Connect Biopharma Holdings Limited (CNTB) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CNTB Revenue Growth
Revenue Breakdown (FY 2024)
CNTB's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CNTB Revenue Analysis (2019–2024)
As of May 8, 2026, Connect Biopharma Holdings Limited (CNTB) generated trailing twelve-month (TTM) revenue of $26.1 million, reflecting significant decline in growth of -99.8% year-over-year. The most recent quarter (Q2 2025) recorded $48,000 in revenue, down 97.5% sequentially.
Looking at the longer-term picture, CNTB's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $26.0 million in 2024, representing a new all-time high.
Revenue diversification analysis shows CNTB's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ABBV (+8.6% YoY), REGN (+5.9% YoY), and ARQT (+95.3% YoY), CNTB has underperformed the peer group in terms of revenue growth. Compare CNTB vs ABBV →
CNTB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CNTBCurrent | $26M | -99.8% | - | -86.2% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 DAWN | $158M | +20.6% | - | -80.8% | |
 RXST | $134M | -19.5% | +55.7% | -35.8% |
CNTB Historical Revenue Data (2019–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $26.0M | - | $26.0M | 100.0% | $-22,452,000 | -86.2% |
| 2023 | $0 | - | $-988,000 | - | $-62,074,000 | - |
| 2022 | $0 | - | $-1,030,634 | - | $-117,661,644 | - |
| 2021 | $0 | - | $0 | - | $-99,151,869 | - |
| 2020 | $0 | - | $0 | - | $-30,295,313 | - |
| 2019 | $0 | - | $0 | - | $-15,993,449 | - |
See CNTB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNTB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNTB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCNTB — Frequently Asked Questions
Quick answers to the most common questions about buying CNTB stock.
Is CNTB's revenue growth accelerating or slowing?
CNTB revenue declined -99.8% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $26M. This reverses the prior growth trend.
What is CNTB's long-term revenue growth rate?
Connect Biopharma Holdings Limited's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -99.8% is below this long-term average.
How is CNTB's revenue distributed by segment?
CNTB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.